An open trial of reboxetine in HIV-seropositive outpatients with major depressive disorder

The prevalence of major depressive disorder (MDD) in human immunodeficiency virus (HIV)-seropositive patients is higher than in the general population. The treatment of comorbidities of HIV infection, such as depression, is an important target in the clinical management of these patients. The use of...

Full description

Saved in:

Bibliographic Details
Published in:	The journal of clinical psychiatry Vol. 64; no. 4; pp. 421 - 424
Main Authors:	CARVALHAL, Adriana S, BELMONTE DE ABREU, Paulo, SPODE, Alessandra, CORREA, Joel, KAPCZINSKI, Flavio
Format:	Journal Article
Language:	English
Published:	Memphis, TN Physicians Postgraduate Press 01-04-2003
Subjects:	Adolescent Adrenergic Uptake Inhibitors - adverse effects Adrenergic Uptake Inhibitors - therapeutic use Adult Ambulatory Care Antidepressive Agents - adverse effects Antidepressive Agents - therapeutic use Biological and medical sciences Comorbidity Depressive Disorder - diagnosis Depressive Disorder - drug therapy Depressive Disorder - epidemiology Female HIV Seropositivity - epidemiology Humans Hyperhidrosis - chemically induced Male Medical sciences Middle Aged Morpholines - adverse effects Morpholines - therapeutic use Nausea - chemically induced Neuropharmacology Pharmacology. Drug treatments Psychiatric Status Rating Scales Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopharmacology Reboxetine Sleep Initiation and Maintenance Disorders - chemically induced Treatment Outcome Disease Psychotropic Toxicity Reuptake inhibitor Adult Antidepressant agent Human Mood disorder Immunopathology Reboxetine Treatment efficiency Depression AIDS Immune deficiency Infection Symptomatology Concomitant disease Chemotherapy Treatment Follow up study Viral disease Young adult Severity score Norepinephrine Somatic disease
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The prevalence of major depressive disorder (MDD) in human immunodeficiency virus (HIV)-seropositive patients is higher than in the general population. The treatment of comorbidities of HIV infection, such as depression, is an important target in the clinical management of these patients. The use of antidepressants in HIV patients can be complicated by the pharmacokinetic interaction between antidepressants and antiretroviral agents. Several antidepressants and antiretrovirals are metabolized by cytochrome P450 (CYP450). Reboxetine is a noradrenergic antidepressant that is not metabolized by CYP450 and may offer a valuable option in the treatment of MDD in HIV-seropositive patients. Twenty HIV-infected outpatients with MDD according to DSM-IV criteria were treated with reboxetine, 8 mg/day, for 12 weeks within an open trial design. Outcome measures included the Montgomery-Asberg Depression Rating Scale (MADRS) and a side effect profile. Data were gathered from July 2000 to March 2001. Seventy-five percent of patients (N = 15) completed the trial. All patients who completed the trial had an improvement equal to or higher than a 50% reduction in their MADRS scores at endpoint. The most frequent adverse effects were insomnia, sweating, and shivering. Within this open trial, reboxetine was found to be effective in reducing depressive symptoms in HIV illness. The rate of dropout (25%) suggests that reboxetine may be well tolerated in this population.
ISSN:	0160-6689 1555-2101
DOI:	10.4088/JCP.v64n0411